Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Optaflu in Adults and Elderly
NCT01422512Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of TIVc in influenza, sponsored by Novartis. Primary endpoint: Antibody response as measured by hemagglutination inhibition (HI) assay at 22 days. Started Sep 2011; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01422512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01422512.